Reducing Risk of Dementia through De-prescribing (R2D2)

项目摘要/摘要 美国老年医学会和医疗保险和医疗补助服务中心都已经确定 抗胆碱能药作为老年人的不适当药物，因为它们的不良认知影响导致 阿尔茨海默病和相关痴呆症(ADRD)风险增加。每年，多达30%的老年人 美国人至少使用其中一种药物，超过50%的人使用至少一种强烈的抗胆碱能药物。 五年了。尽管意识到了这些不利的认知影响，但在以下方面，患病率并没有下降 在过去二十年里。几项研究发现，在这些药物的使用者中，ADRD的风险更高， 然而，目前尚不清楚在当前使用者中停止使用这些药物是否会导致急性和持续性 认知能力的提高。 我们提出了一项名为“通过停药降低痴呆症风险(R2D2)”的新试验，以确定 药剂师主导的停药方案改善初级保健老年人认知能力的有效性 目前正在使用一种抗胆碱能药物。我们将把干预重点放在高中生的初级保健患者身上 由于当前的认知投诉或在认知方面至少犯了一个错误而导致认知能力下降的风险 筛查工具，但不包括痴呆症患者。该设计将是一项整群随机试验，随机 医生将污染风险降至最低。参与者将被随机分配到常规护理(UC)或主动护理 干预组(ACT)将接受以药剂师为基础的非处方干预，以我们的 之前的工作。R2D2研究将招募344名老年人来确定干预对认知的影响 在基线后6、12、18和24个月。这项试验将监测抑郁症干预的安全性， 焦虑、疼痛、失眠和生活质量。我们假设ACT组在以下方面的分数会更高 认知评估，安全措施没有变化，生活质量得分与 照常照看。 如果我们的假设成立，这项研究将证明抗胆碱药物的不良认知影响是 ADRD高危老年人的可逆性，为进一步的工作测试认知时间提供支持 衰退或痴呆症是主要结果。延缓认知障碍发病的干预措施和 痴呆症将对老龄人口的护理质量和成本产生重大影响。

PROJECT SUMMARY/ABSTRACT Both the American Geriatrics Society and the Center for Medicare and Medicaid Services have identified anticholinergics as inappropriate medications in older adults due to their adverse cognitive effects causing an increased risk of Alzheimer's disease and related dementias (ADRD). Every year, as many as 30% of older Americans use at least one of these medications, and more than 50% use at least one strong anticholinergic in five years. Despite awareness of these adverse cognitive effects, there has been no decline in prevalence over the last two decades. Several studies have identified higher risks of ADRD among users of these medications, however it is unknown whether stopping these medications in current users results in acute and sustained improvements in cognition. We propose a new trial called “Reducing Risk of Dementia through De-prescribing (R2D2)” to determine the efficacy of a pharmacist-driven de-prescribing protocol to improve cognition among primary care older adults currently using an anticholinergic medication. We will focus the intervention on primary care patients at high risk of cognitive decline due to current cognitive complaints or those making at least one error on a cognitive screening tool, while excluding those with dementia. The design will be a cluster randomized trial, randomizing physicians to minimize risk of contamination. Participants will be randomized to usual care (UC) or an active intervention group (ACT) that will receive a pharmacist-based de-prescribing intervention modeled after our prior work. The R2D2 study will enroll 344 older adults to determine the impact of the intervention on cognition at 6, 12, 18, and 24 months after baseline. The trial will monitor the safety of the intervention on depression, anxiety, pain, insomnia, and quality of life. We hypothesize that the ACT group will have better scores on cognitive assessments, no change in safety measures, and improvement in quality of life scores compared to usual care. If our hypothesis holds, this study would prove that the adverse cognitive effects of anticholinergics are reversible in older adults at high risk of ADRD, providing support for further work testing time to cognitive decline or dementia as a primary outcome. Interventions delaying the onset of cognitive impairment and dementia will have a significant impact on both the quality and costs of care of the aging population.